Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Prepaid Assets: 2021-2025

Historic Prepaid Assets for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $6.4 million.

  • ARS Pharmaceuticals' Prepaid Assets rose 139.86% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 139.86%. This contributed to the annual value of $6.9 million for FY2024, which is 104.58% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Prepaid Assets stood at $6.4 million, which was down 13.72% from $7.4 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Prepaid Assets' 5-year high stood at $11.6 million during Q1 2025, with a 5-year trough of $667,000 in Q4 2021.
  • Its 3-year average for Prepaid Assets is $4.6 million, with a median of $2.8 million in 2023.
  • Per our database at Business Quant, ARS Pharmaceuticals' Prepaid Assets spiked by 397.60% in 2022 and then tumbled by 62.58% in 2023.
  • ARS Pharmaceuticals' Prepaid Assets (Quarterly) stood at $667,000 in 2021, then soared by 397.60% to $3.3 million in 2022, then climbed by 1.42% to $3.4 million in 2023, then soared by 104.58% to $6.9 million in 2024, then soared by 139.86% to $6.4 million in 2025.
  • Its last three reported values are $6.4 million in Q3 2025, $7.4 million for Q2 2025, and $11.6 million during Q1 2025.